BackSino Biopharmaceutical Limited Overview

Sino Biopharmaceutical Limited Receivables

Track Sino Biopharmaceutical Limited's receivables ($11B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$10.68B
↑ 30.93% YoYΔ $2.52B vs prior year quarter

Peer trimmed avg / median

Loading

Sino Biopharmaceutical Limited Receivables History

Loading

Sino Biopharmaceutical Limited vs. peers: Receivables Comparison

Loading

Sino Biopharmaceutical Limited Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Sino Biopharmaceutical Limited (SBMFF) FAQ

As of the most recent data (June 2026), SBMFF shows a receivables of $11B. That compares with $8.2B in the prior-year period — up 30.9% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SBMFF's receivables is now $11B (was $8.2B) — a 30.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Sino Biopharmaceutical Limited is outperforming or lagging.

Tracking SBMFF's receivables over time shows whether Sino Biopharmaceutical Limited is scaling, shrinking, or reshaping that part of the business. The current reading is $11B That compares with $8.2B in the prior-year period — up 30.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Sino Biopharmaceutical Limited's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $11B) with ownership activity and broader fundamentals.

Sino Biopharmaceutical Limited's receivables is $11B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.